Product Information
RIFABUTIN 150 MG CAPSULE is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $8.1363 per EA under NDC 70954004110. Its NADAC has been published 177 times since May 17, 2023.
FDA first approved this application on Dec 17, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
ANI Pharmaceuticals, Inc.NDC
70954004110
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIFABUTINApproval Type
Generic (ANDA)
FDA Application
ANDA215041FDA Approved
12/17/2021
TE Code
AB
On Market Since
12/17/2021
Pharmacological Classes
Price Statistics
The NADAC for RIFABUTIN 150 MG CAPSULE has been published 177 times since May 17, 2023, and over the history we have for it it has declined 24.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $8.1363 per EA |
|---|---|
| All-time high | $10.7596 (Jun 14, 2023) |
| All-time low | $7.3273 (Jun 19, 2024) |
| 52-week high | $9.6009 |
| 52-week low | $8.1008 |
| Median price | $9.3276 |
| Average price | $9.3564 |
| Largest weekly change | -18.0% (May 22, 2024) |
| Weeks tracked | 177 |
| Tracking since | May 17, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Rifabutin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
ANI Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rifabutin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIFABUTIN 150 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RIFABUTIN 150 MG CAPSULE, manufactured by ANI Pharmaceuticals, Inc., is $8.1363 per EA (NDC 70954004110), effective Sep 30, 2026.
How has the price of RIFABUTIN 150 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RIFABUTIN 150 MG CAPSULE has declined 24.4%. It has been tracked across 177 weekly CMS publications since May 17, 2023.
What are the highest and lowest recorded NADAC prices for RIFABUTIN 150 MG CAPSULE?
Since May 17, 2023, the NADAC for RIFABUTIN 150 MG CAPSULE has ranged from a low of $7.3273 (Jun 19, 2024) to a high of $10.7596 (Jun 14, 2023), with a median of $9.3276 per EA.
Are there cheaper alternatives to RIFABUTIN 150 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of RIFABUTIN 150 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures RIFABUTIN 150 MG CAPSULE?
RIFABUTIN 150 MG CAPSULE (NDC 70954004110) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.